{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:56:33Z","timestamp":1790996193328,"version":"4.1.0"},"reference-count":52,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>While lenalidomide has been the established standard of care for maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma, risk-adapted maintenance strategies with the addition of proteasome inhibitors can provide additional benefit in high-risk disease. The widespread use of anti-CD38 monoclonal antibodies (mAbs) in induction and consolidation has further disrupted this paradigm, offering the use of anti-CD38 mAbs in maintenance. Novel immunotherapeutic approaches and minimal residual disease\u2013guided maintenance strategies are being actively investigated. The evolution of maintenance strategies provides a window to a future where maintenance therapy is not only more effective at sustaining deep and durable responses but also more dynamic with careful de-escalation strategies.<\/jats:p>","DOI":"10.1182\/hematology.2025000732","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:08:59Z","timestamp":1764943739000},"page":"412-423","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Choosing the optimal maintenance strategy in multiple myeloma"],"prefix":"10.1182","volume":"2025","author":[{"given":"Benjamin","family":"Puliafito","sequence":"first","affiliation":[{"name":"Center for Multiple Myeloma, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Cirstea","sequence":"additional","affiliation":[{"name":"Center for Multiple Myeloma, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noopur","family":"Raje","sequence":"additional","affiliation":[{"name":"Center for Multiple Myeloma, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"19","key":"2025120616335967300_hem2025000732C1","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"2025120616335967300_hem2025000732C2","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"2025120616335967300_hem2025000732C3","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"2025120616335967300_hem2025000732C4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"29","key":"2025120616335967300_hem2025000732C5","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"issue":"14","key":"2025120616335967300_hem2025000732C6","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"2025120616335967300_hem2025000732C7","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"2025120616335967300_hem2025000732C8","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/blood-2024-205788","article-title":"Optimising the duration of therapy for newly diagnosed transplant ineligible patients: analysis of long term follow up data from the UK MRA myeloma XI trial","volume":"144","author":"Pawlyn","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025120616335967300_hem2025000732C9","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1182\/blood-2024-205871","article-title":"MRD and molecular risk status help to define optimal maintenance delivery strategies after ASCT: long term outcomes of the UK MRA myeloma XI trial comparing lenalidomide to observation","volume":"144","author":"Jackson","year":"2024","journal-title":"Blood"},{"issue":"14","key":"2025120616335967300_hem2025000732C10","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood.2022018339","article-title":"Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial","volume":"141","author":"Panopoulou","year":"2023","journal-title":"Blood"},{"issue":"24","key":"2025120616335967300_hem2025000732C11","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J Clin Oncol"},{"issue":"11","key":"2025120616335967300_hem2025000732C12","doi-asserted-by":"crossref","first-page":"e70052","DOI":"10.1002\/hem3.70052","article-title":"Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65\/GMMG-HD4 trial","volume":"8","author":"Mai","year":"2024","journal-title":"Hemasphere"},{"issue":"2","key":"2025120616335967300_hem2025000732C13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/leu.2017.211","article-title":"Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65\/GMMG-HD4 trial","volume":"32","author":"Goldschmidt","year":"2018","journal-title":"Leukemia"},{"issue":"12","key":"2025120616335967300_hem2025000732C14","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","article-title":"Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"2025120616335967300_hem2025000732C15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(22)00693-3","article-title":"Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial","volume":"24","author":"Mina","year":"2023","journal-title":"Lancet Oncol"},{"issue":"3","key":"2025120616335967300_hem2025000732C16","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/leu.2013.335","article-title":"Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients","volume":"28","author":"Nooka","year":"2014","journal-title":"Leukemia"},{"issue":"17","key":"2025120616335967300_hem2025000732C17","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1200\/JCO.19.02515","article-title":"Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma","volume":"38","author":"Joseph","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10168","key":"2025120616335967300_hem2025000732C18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","article-title":"Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"393","author":"Dimopoulos","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"2025120616335967300_hem2025000732C19","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1182\/blood-2021-150476","article-title":"Interim analyses of overall survival (OS) from the TOURMALINE MM3 & MM4 studies of ixazomib maintenance following primary therapy in multiple myeloma (MM)","volume":"138","author":"Dimopoulos","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2025120616335967300_hem2025000732C20","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1038\/s41375-022-01691-1","article-title":"Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma","volume":"36","author":"Slade","year":"2022","journal-title":"Leukemia"},{"issue":"18","key":"2025120616335967300_hem2025000732C21","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1182\/blood.2022019531","article-title":"Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma","volume":"142","author":"Rosi\u00f1ol","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2025120616335967300_hem2025000732C22","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","volume":"25","author":"Moreau","year":"2024","journal-title":"Lancet Oncol"},{"issue":"6","key":"2025120616335967300_hem2025000732C23","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood.2024027620","article-title":"Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results","volume":"146","author":"Corre","year":"2025","journal-title":"Blood"},{"issue":"3","key":"2025120616335967300_hem2025000732C24","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood.2024025746","article-title":"Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study","volume":"145","author":"Badros","year":"2025","journal-title":"Blood"},{"issue":"4","key":"2025120616335967300_hem2025000732C25","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"16","key":"2025120616335967300_hem2025000732C26","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1200\/JCO.2024.42.16_suppl.7502","article-title":"Daratumumab (DARA) + bortezomib\/lenalidomide\/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): analysis of minimal residual disease (MRD) in the PERSEUS trial","volume":"42","author":"Rodr\u00edguez-Otero","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025120616335967300_hem2025000732C27","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1182\/blood-2024-201736","article-title":"Daratumumab plus lenalidomide (D-R) versus lenalidomide (R) alone as maintenance therapy in newly diagnosed multiple myeloma (NDMM) after transplant: analysis of the phase 3 Auriga study among clinically relevant subgroups","volume":"144","author":"Foster","year":"2024","journal-title":"Blood"},{"issue":"22","key":"2025120616335967300_hem2025000732C28","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"2025120616335967300_hem2025000732C29","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S1470-2045(25)00018-X","article-title":"Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open- label, randomised, multicentre, phase 3 trial","volume":"26","author":"San-Miguel","year":"2025","journal-title":"Lancet Oncol"},{"issue":"4","key":"2025120616335967300_hem2025000732C30","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"issue":"17","key":"2025120616335967300_hem2025000732C31","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"2025120616335967300_hem2025000732C32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma","volume":"42","author":"Leypoldt","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025120616335967300_hem2025000732C33","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1182\/blood-2024-201086","article-title":"Extended intensified consolidation and maintenance improve ultra high-risk multiple myeloma patient outcome: long-term follow-up of the Ukmra Optimum\/Muknine trial","volume":"144","author":"Kaiser","year":"2024","journal-title":"Blood"},{"issue":"15","key":"2025120616335967300_hem2025000732C34","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1200\/JCO.2021.39.15_suppl.8001","article-title":"Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): results of the UK optimum\/MUKnine trial","volume":"39","author":"Kaiser","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025120616335967300_hem2025000732C35","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2023-177546","article-title":"Results of the phase III randomized iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients","volume":"142","author":"Gay","year":"2023","journal-title":"Blood"},{"issue":"16","key":"2025120616335967300_hem2025000732C36","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1200\/JCO.2025.43.16_suppl.7502","article-title":"Sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial)","volume":"43","author":"Gay","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025120616335967300_hem2025000732C37","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S2352-3026(24)00070-X","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial","volume":"11","author":"O'Donnell","year":"2024","journal-title":"Lancet Haematol"},{"issue":"1","key":"2025120616335967300_hem2025000732C38","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1182\/blood-2021-146274","article-title":"A phase II study of lenalidomide, ixazomib, dexamethasone, and daratumumab in transplant- ineligible patients with newly diagnosed multiple myeloma (AFT-41)","volume":"138","author":"O'Donnell","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2025120616335967300_hem2025000732C39","doi-asserted-by":"crossref","first-page":"7289","DOI":"10.1182\/blood-2022-159756","article-title":"MajesTEC-4 (EMN30): a phase 3 trial of teclistamab + lenalidomide versus lenalidomide alone as maintenance therapy following autologous stem cell transplantation in patients with newly diagnosed multiple myeloma","volume":"140","author":"Zamagni","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2025120616335967300_hem2025000732C40","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2024-205608","article-title":"Phase 3 study of teclistamab (Tec) in combination with lenalidomide (Len) and tec alone versus Len alone in newly diagnosed multiple myeloma (NDMM) as maintenance therapy following autologous stem cell transplantation (ASCT): safety run-in (SRI) results from the majestec-4\/EMN30 trial","volume":"144","author":"Zamagni","year":"2024","journal-title":"Blood"},{"issue":"16","key":"2025120616335967300_hem2025000732C41","article-title":"MagnetisMM-7: an open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post-transplant patients with newly diagnosed multiple myeloma","volume":"41","author":"Manteca","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025120616335967300_hem2025000732C42","first-page":"208","article-title":"Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed MM: first results of the phase 2 EMN26 study","volume":"142","author":"Touzeau","year":"2023","journal-title":"Blood"},{"issue":"S3","key":"2025120616335967300_hem2025000732C43","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/01.HS9.0000843592.63620.b4","article-title":"S175: ATLAS: a phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma","volume":"6","author":"Dytfeld","year":"2022","journal-title":"HemaSphere"},{"issue":"5","key":"2025120616335967300_hem2025000732C44","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa2505133","article-title":"Lambert J, Hulin C, et al","volume":"393","author":"Perrot","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2025120616335967300_hem2025000732C45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2020-142913","article-title":"Phase III study of daratumumab\/rhuph20 (nsc-810307) + lenalidomide or lenalidomide as post-autologous stem cell transplant maintenance therapy in patients with multiple myeloma (MM) using minimal residual disease to direct therapy duration (DRAMMATIC study): SWOG s1803","volume":"136","author":"Krishnan","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2025120616335967300_hem2025000732C46","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1182\/blood-2023-190011","article-title":"Free from drug therapy in multiple myeloma (FREEDMM): MRD-based cessation of maintenance","volume":"142","author":"Avila","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2025120616335967300_hem2025000732C47","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol"},{"issue":"1","key":"2025120616335967300_hem2025000732C48","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41408-024-01156-x","article-title":"Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)","volume":"14","author":"Derman","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"2025120616335967300_hem2025000732C49","article-title":"MRD-guided sequential therapy for deep response in newly diagnosed multiple myeloma (NDMM) \u2013 Master-2 trial","volume":"144","author":"Dhakal","year":"2024","journal-title":"Blood"},{"issue":"10","key":"2025120616335967300_hem2025000732C50","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","article-title":"Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"2025120616335967300_hem2025000732C51","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"2025120616335967300_hem2025000732C52","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat Med"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/412\/2470024\/412puliafito.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/412\/2470024\/412puliafito.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:34:07Z","timestamp":1765056847000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2025\/1\/412\/556892\/Choosing-the-optimal-maintenance-strategy-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,5]]},"published-print":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2025000732","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,5]]},"published":{"date-parts":[[2025,12,5]]}}}